Take a look at our previous reports:

Key achievements in 2022

2022

January

Jyseleca® approved in UC in Great Britain

March

Jyseleca® approved in UC in Japan

April

Appointment of Dr. Paul Stoffels as CEO and Chairman

June

Expansion into oncology with acquisitions of CellPoint (NL) and AboundBio (US)

October

Positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

November

New R&D strategy and fit-for-purpose organization

Initial encouraging results from FILOSOPHY real-world study of filgotinib in RA

CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

December

Initial encouraging Phase 1/2 results for CD19 CAR-T in rrNHL manufactured at point-of-care

Set-up of new Management Committee and announced changes to the Executive Committee